KRS Capital Management’s Procept Biorobotics PRCT Stock Holding History

KRS Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$787K	Sell	43,208 -2,402	-5%	-$47.9K	0.35%	48
2026 Q2	$1.03M	Sell	45,610 -125	-0.3%	-$3.13K	0.48%	38
2026 Q1	$1.14M	Buy	45,735 +20	+0%	+$564	0.7%	31
2025 Q4	$1.44M	Sell	45,715 -295	-0.6%	-$9.8K	0.83%	23
2025 Q3	$1.64M	Buy	46,010 +20	+0%	+$913	0.99%	19
2025 Q2	$2.65M	Sell	45,990 -400	-0.9%	-$22.6K	1.77%	9
2025 Q1	$2.7M	Sell	46,390 -65	-0.1%	-$4.44K	2.15%	8
2024 Q4	$3.74M	Buy	46,455 +225	+0.5%	+$19.2K	2.64%	6
2024 Q3	$3.7M	Buy	46,230 +125	+0.3%	+$8.88K	2.7%	5
2024 Q2	$2.82M	Buy	+46,105	New	+$2.74M	2.11%	7

Other funds holding PRCT

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Frank Rimerman Advisors Palo Alto, California $1.81B AUM 32.96% 1-Year Est. Return

Taylor Frigon Capital Management Scottsdale, Arizona $197M AUM 35.01% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Inscription Capital Houston, Texas $906M AUM 27.95% 1-Year Est. Return

Enclave Advisors Austin, Texas $793M AUM 15.9% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

KRS Capital Management's PRCT Position: Q3 2026 in Review

KRS Capital Management reduced its Procept Biorobotics (PRCT) stake by 5.3% in Q3 2026, selling an estimated $47.9K and leaving 43,208 shares worth $787K. The position accounts for 0.35% of the portfolio, ranked #48.

KRS Capital Management first reported a position in PRCT in Q2 2024 and has held it in 10 quarters since. The position peaked at $3.74M in Q4 2024. 51 funds tracked by Wall St. Rank hold PRCT as of Q3 2026.

KRS Capital Management held 43,208 shares of Procept Biorobotics worth $787K as of Q3 2026.
KRS Capital Management sold 2,402 Procept Biorobotics shares in Q3 2026, an estimated $47.9K.
Procept Biorobotics made up 0.35% of KRS Capital Management's portfolio in Q3 2026, its #48 holding.
KRS Capital Management first reported a position in Procept Biorobotics in Q2 2024 and has held it in 10 quarters since.
KRS Capital Management's Procept Biorobotics position peaked at $3.74M in Q4 2024.
51 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2026.

Based on KRS Capital Management's 13F filing for Q3 2026, filed 16 Oct 2026.